MacroGenicsMGNX
MGNX
About: Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Employees: 341
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
0% more funds holding
Funds holding: 127 [Q4 2024] → 127 (+0) [Q1 2025]
4.11% less ownership
Funds ownership: 89.37% [Q4 2024] → 85.26% (-4.11%) [Q1 2025]
12% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 41
61% less call options, than puts
Call options by funds: $75K | Put options by funds: $191K
63% less capital invested
Capital invested by funds: $182M [Q4 2024] → $68.3M (-$114M) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2
32%
upside
Avg. target
$3.25
114%
upside
High target
$5
229%
upside
4 analyst ratings
1 positive
25%
3 neutral
75%
0 negative
0%
B. Riley Securities Mayank Mamtani | 97%upside $3 | Neutral Maintained | 20 May 2025 |
Stifel Stephen Willey | 229%upside $5 | Hold Maintained | 14 May 2025 |
Barclays Peter Lawson | 97%upside $3 | Overweight Maintained | 14 May 2025 |
HC Wainwright & Co. Robert Burns | 32%upside $2 | Neutral Maintained | 25 Mar 2025 |
Financial journalist opinion
Based on 4 articles about MGNX published over the past 30 days
Neutral
Seeking Alpha
3 days ago
MacroGenics: Working On That Road To Recovery
I maintain a tentative 'Buy' on MacroGenics, Inc., but acknowledge increased risk after the vobra duo failure and ongoing cash flow challenges. Lorigerlimab is now the lead pipeline candidate, with key phase 2 data expected in late 2025, and additional programs like MGC-026 and MGC-028 progressing. The recent royalty deal extends the cash runway, but liquidity concerns remain, and further asset sales or dilution may be necessary.
Neutral
GlobeNewsWire
4 days ago
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard) MacroGenics' cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that it has entered into a royalty purchase agreement with Sagard in exchange for a capped royalty interest on future global net sales of ZYNYZ (retifanlimab-dlwr). ZYNYZ is a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte pursuant to an exclusive global collaboration and license agreement in October 2017.
Neutral
GlobeNewsWire
1 week ago
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL.
Negative
Zacks Investment Research
3 weeks ago
4 Medical Product Stocks to Watch From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.
Negative
Zacks Investment Research
1 month ago
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.84 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results
ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2025.
Neutral
GlobeNewsWire
1 month ago
MacroGenics Announces Date of First Quarter 2025 Financial Results
ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.
Neutral
GlobeNewsWire
1 month ago
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month:
Positive
Zacks Investment Research
1 month ago
4 Medical Product Stocks to Buy From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.
Negative
Zacks Investment Research
2 months ago
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for MacroGenics (MGNX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Charts implemented using Lightweight Charts™